Josep Bassaganya-Riera, NImmune Biopharma
March 22, 2023 06:00 AM EDTUpdated 06:47 AM
Startups

Ex­clu­sive: Af­ter get­ting his drug back, Lan­dos founder as­sem­bles new start­up for the big PhI­II test

Amber Tong

By the time Josep Bas­saganya-Ri­era stepped down as found­ing CEO of Lan­dos Bio­phar­ma in 2021, the com­pa­ny had racked up Phase II da­ta for its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­vo Nordisk is feel­ing the com­pe­ti­tion from com­pound­ed GLP-1s, ex­ec says

Am­gen an­nounces hold on Phase 1 obe­si­ty can­di­date, pipeline cuts

GSK de­fi­ant against vac­cine chal­lenges, will pri­or­i­tize oth­er growth ar­eas

Small per­son­al­ized vac­cine tri­al sees progress in late-stage kid­ney can­cer

Ku­ra's AML drug pass­es key study in ad­vanced pa­tients, plans next steps with FDA and new­ly di­ag­nosed stud­ies

Pfiz­er says it has at least $10B avail­able for deals in 2025, with a fo­cus on pipeline

A service from the Financial Times